Tuesday, 10 December 2019

Tendinitis Treatment Market Volume Forecast and Value Chain Analysis 2019

An expert on premium research reports, Market Research Future predicts that Global tendinitis treatment market is expected to grow at the CAGR of ~3.8% during the forecast period and is estimated to reach USD 426.4 million by 2023. According to a recent study report published by the Market Research Future, the global tendinitis treatment market is expected to gain eminence over the forecast period. The market is forecasted to demonstrate a steady growth by 2023, surpassing USD 426.4 million with a constant CAGR during the anticipated period (2017 – 2023).
Tendinitis is the inflammation of the tendon, thick cords that attach the muscles to the bone. The inflammation occurs as a result of sudden injury to the tendon, repetitive movement or disease condition such as diabetes, rheumatoid arthritis, gout, Reiter's syndrome or lupus. In case of patients with gout, the uric acid crystals appear in the tendon sheath leading to friction. Tendinitis is found to be prevalent among athletes and is one of the common sport injuries in sport players, especially tennis, golf and others. Various pharmacological and non-pharmacological treatments are available for the treatment of tendinitis. Non-steroidal anti-inflammatory drugs (NSAIDs) constitute the preliminary treatment options. Other treatments including physical therapy, rest, and occupational therapy. Surgery is the last resort for tendinitis, and is only recommended in case of severe damage to the tendon that cannot be treated using pharmacological treatment options.
Key players for Global Tendinitis Treatment Market:                                   
  • Almatica Pharma, Inc. (US),
  • AstraZeneca (US),
  • Bayer (Germany),
  • Boehringer Ingelheim Pharmaceuticals, Inc. (US),
  • Merck & Co., Inc (US),
  • Pfizer (US).
Intended Audience:
  • Tendinitis medicines manufacturers
  • Tendinitis medicines and treatment providers
  • Medical Research laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors
Segments:
Global tendinitis treatment market has been segmented on the basis of condition which comprises of tennis elbow, golfer's elbow, pitcher's shoulder, swimmer's shoulder, jumper's knee, and others.
On the basis of treatments, the market has been segmented into medications, therapy, surgical repair, and others. Medication sub-segmented into pain relievers, corticosteroids, Platelet-Rich Plasma (PRP), and others. Therapy is further sub-segmented into hot and cold therapy, physical therapy, occupational therapy, and others.
On the basis of diagnosis, the market is segmented into physical exam, imaging tests, and others. Imaging test is sub-segmented into ultrasound, Magnetic Resonance Imaging (MRI) scans, and others.
On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.
Regional analysis
Considering the global scenario of the market, America is the top contributor in this market. The Americas mainly includes North America and South America. Due to developed healthcare infrastructure and increasing R&D funding, US is dominating country in this region. Europe is second largest market for tendinitis treatment. Due to innovative product development and rapid adoption of new treatments, Germany is dominating this market. Asia Pacific is witnessing rapid growth in this market which is mainly due to rapidly changing healthcare sector, increasing awareness, and rising healthcare expenditure. Middle East and Africa is expected to have limited growth while Middle Eastern countries are expected to dominate this market during the forecast period.
Competitive Analysis
The market for tendinitis treatment is characterised by the presence of several well-established and small players, the global market of tendinitis treatment appears to be highly competitive and fragmented. Major players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The tendinitis treatment market appears to be highly competitive owing to the presence of several large and small key players accounting for a substantial market share. Many leading players are concentrated in the Americas owing to well-established market and high healthcare expenditures; these players have expanded their market in other region as well. Furthermore, the companies such as Abbott, AstraZeneca, Teva, and Pfizer are well-established in European market. The major four players namely Abbott, AstraZeneca, Teva, and Pfizer accounted for more than 17% share of the Americas and Europe tendinitis market.
In April 2017, Pfizer entered into a merger with Allergan to gain access for Allergan's portfolio including Botox, Viagra, the Prevnar pneumonia vaccine, and treatments for ailments including Alzheimer’s and rheumatoid arthritis.
Furthermore, in July 2017, Merck & Co.Inc & AstraZeneca entered into strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s LYNPARZA (olaparib) for multiple cancer types.   
Furthermore, in November 2016, AstraZeneca announced a licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc., for the global rights to MEDI2070.
Moreover, May 2014, the company acquired Merck & Co., Inc.’s non-prescription business to become the OTC leader in North America and Latin America & achieve top global positions in key OTC product categories.
Therefore, the growing key business strategies will help the key competitors to expand their presence in various parts of the globe for their competitive products and will has spurred the growth of the market.  
Browse Complete 108 Pages Premium Research Report Enabled with 121 Respective Tables and Figures @  https://www.marketresearchfuture.com/reports/tendinitis-treatment-market-3876
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Mitochondrial Myopathies Market 2019 Analysis, Opportunities and Forecast to 2023

Market scenario:
The growing number of m mitochondrial myopathy invalids is likely to spur the global mitochondrial myopathies market growth over the forecast period. The major issue with mitochondrial myopathies is that, it is a genetic disorder and till today, has no proper cure. This, is observed to generate boundless scope for research. The strong support of governments, across the world, is encouraging researchers for undertaking numerous research and developmental projects to develop effective treatment for mitochondrial myopathies. Hence, this factor can cast a positive influence on the mitochondrial myopathies market growth. The availability of certain diagnostic aids for the mitochondrial myopathies and their precise results are also expected to amplify the market growth. The presence of reimbursement and medical insurance policies for rare genetic diseases like mitochondrial myopathies can rise the profit margins of the mitochondrial myopathies market.
However, the unavailability of specific treatment regime for mitochondrial myopathies and lack of cognisance of the availability of enhanced diagnostic solutions for detecting mitochondrial myopathies are certain factors, which can interfere the mitochondrial myopathies market expansion.
The Mitochondrial Myopathies is expected to reach $ 600 million by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.
Top-Notch Key Players                                         
MRFR profiled eminent companies which are operating in the global mitochondrial myopathies market. They are; Khondrion BV, Reata Pharmaceuticals, Inc., GeneDx, Stealth BioTherapeutics, NeuroVive Pharmaceutical AB, Centogene AG, and Raptor Pharmaceutical Corp.
Segments:
Type, diagnostic tests, and therapies are segments, under which the global mitochondrial myopathies market has been studies.
Based on the type, the mitochondrial myopathies market has been segmented into Mitochondrial encephalomyopathy, Kearns-Sayre syndrome (KSS), Pearson syndrome, Mitochondrial DNA depletion syndrome (MDS), Leigh syndrome, Myoclonus epilepsy with ragged red fibers (MERRF), Progressive external ophthalmoplegia (PEO), Mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE), and Neuropathy, ataxia and retinitis pigmentosa (NARP).
Based on therapies, the mitochondrial myopathies market has been segmented into vitamins, coenzymes and antioxidants, supportive, dietary, and other.
Based on diagnostic aids, the mitochondrial myopathies market has been segmented into genetic test, muscle biopsy, and blood enzyme test.
Regional analysis
Based on the region, the global mitochondrial myopathies market has been studied across North America, Asia Pacific, Europe, the Middle East Asia and Africa.
The US in North America, is to hold the largest share of the regional market, while, North America dominates the global mitochondrial myopathies market. The strong economy empowering North America is likely to bolster the market growth over the assessment period. Furthermore, the increasing number of screening tests is also expected to escalate the US market growth. To illustrate, in the U.S., the new-born screening is performed on a infant, despite, its parent’s health insurance status or ability to bear medical expenses or charged minimum for the testing. The expansion of mitochondrial myopathies patient pool and surge in the government support for research and development undertakings are other factors, which can drive up the American mitochondrial myopathies market. Continuous technical upgradation backing medical advancements are identified to spur the South American mitochondrial myopathies market. The existence of private health insurance plans like Medicaid and the Children's Health Insurance Program (CHIP) and likely to cast a positive impact on the regional mitochondrial myopathies market expansion.
The Asia Pacific region is to exhibit a fast-paced growth for the mitochondrial myopathies market. Emerging economies like India and China are likely to witness a considerable market growth due to the rising need to meet the existing medical backlogs.  However, owing to political loopholes and fragile economic condition in the Africa, the market can experience a stagnancy in the growth over the review period. But, the mitochondrial myopathies market is expected to be led by the Gulf nations, particularly Saudi Arabia and UAE.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/mitochondrial-myopathies-market-3684
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Veterinary Imaging Market Growth and Restrain Factors Analysis By 2023

Market Scenario
The Global Veterinary Imaging Market is expected to register a CAGR of 7.14% to reach USD 2167.78 million by 2025. Veterinary imaging is the noninvasive method that helps to diagnose disease by making medical images of the veterinary body. We have various advanced imaging technology used for veterinary patients. Veterinary imaging instruments are used to diagnosis of chronic disease and getting medical images of animals. Notably, the increasing prevalence of zoonotic diseases, significant rise in pet insurance purchases, and increased number of veterinary practitioners are promoting the growth of the veterinary imaging market globally.
The market growth is mainly driven by increasing incidence of zoonotic diseases, increasing expenditure on pet insurance, and technological advancements in veterinary imaging. However, high procedure cost and lack of skilled veterinarians may slow the growth of the market.
 Market Dynamics
Increasing expenditure on the pet is driving the growth of the market. Pet insurance covers various minor to major medical expenses such as accidents, chronic conditions, wellness, and routine care coverage, medication coverage, diagnostic testing and imaging, others. Though pet insurance does not provide 100% coverage, it reimburses around 80% of the total pet medical expenses. According to the North American Pet Health Insurance Association (NAPHIA), North America’s pet health insurance growth was exceeded by 17.2% from 2014 to 2015. It is also reported that the total number of insured pets reached 1.6 million at the end of 2015.
Pet owners spend a lot on routine vet expenses and surgical vet visits. As per the data suggested by The American Pet Products Association (APPA), around 65% of the US population owns a pet, and the US pet industry expenditure in 2015 was USD 60.3 million, which is exceeded to USD 62.8 million. Thus, with the growing spending on animal healthcare, the demand for veterinary diagnosis and the equipment required for the same will also increase, which boosts the growth of global veterinary imaging market.
Segmentation
The global veterinary imaging market is segmented into product type, animal type, therapeutic area, and end user. On the basis of product type, the market is segmented into instruments, veterinary imaging reagents, and veterinary software. On the basis of animal type, it is segmented into small companion animals and large animals. On the basis of the therapeutic area, the veterinary imaging market segmented into orthopedics and traumatology, cardiology, neurology, and oncology. On the basis of end user, the Veterinary Imaging market segmented into hospitals & clinics, and academic institutes.
Regional Analysis
The global veterinary imaging market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest market share in 2018, and the regional market is projected to register a CAGR of 7.62% during the forecast period. The larger share is majorly attributed to the growth in adoption of pet animals, increasing veterinary healthcare expenditure, increasing demand for pet insurance, and increasing pet ownership. According to the report published by the American Pet Products Association, from 2017 to 2018, 68% of the US households or 85 million families have a pet.
Europe is the second-largest market for veterinary imaging owing to the presence of large market players, innovative advanced technology, increasing companion animal ownership, and the presence of veterinaries.
The Asia Pacific region accounted the third-largest market owing to the presence of large animal population, increasing disposal income, increasing nuclear families preferring to have pets and increased investments by the American and European market giants in Asian countries such as China and India. India held a share of 15.9% in the Asia-Pacific veterinary imaging market in 2018.
The market in the Middle East and Africa is constrained due to poor development of the animal industry and the low productivity of the maximum breeds in the region.
Key Players
The prominent players in the global veterinary imaging market are Esaote SpA (Italy), GE Healthcare (US), Medical Imaging/IMCO, Inc. (US), BCF (Scotland), Fujifilm Holding Corporation (Japan), Heska Corporation (US), Diagnostic Imaging System, Inc. (US), Canon Inc. (Tokyo), Carestream Health (US), and Merry X-Ray (US).
The players operating in the global veterinary imaging market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
  • In March 2019, Esaote SpA launched the new ultrasound platform MyLabX8 for increasing efficiency of ultrasound machines and to maintain the workflow.
  • In October 2018, GE Healthcare announced a strategic collaboration with SonoSim to encourage education and training about ultrasound devices. This collaboration is likely to help the company to increase its customer base.
  • In June 2018, Fujifilm Holding Corporation acquired Irvine Scientific Sales Company, Inc. for USD 800 million. With this acquisition, Fujifilm is likely to enter into the cell culture media business.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Ventilator-Associated Pneumonia Market 2019 - Opportunity, Driving Trends and deep study 2023

Market Scenario
According to CDC in 2013, there were 2.8 million traumatic brain injury visits to emergency department and hospitals. The emergency department visits of brain injury patients increased by 47% from 2007. Thus, increasing incidence of TBI drives the growth of the market. Furthermore, increasing geriatric population is likely to fuel the market to grow.  According to the U.S. Census Bureau in 2015, 47.8 million people were 65 years or older, and in 2060, 98.2 million are expected to be 65 years or older.  Such increasing trend in the geriatric population provides favorable backgrounds for the market to grow.
Ventilator-associated pneumonia is a type of lung infection caused to patients who are on ventilators. Ventilator-associated pneumonia is caused mainly due to lung disease, neurologic disease, and trauma to critically ill persons. Diagnosing VAP requires aggressive surveillance combined with the radiographic examination, bedside examination, and microbiologic examinations of respiratory secretions. Growing Intensive Care Unit Admissions due to rising prevalence of respiratory diseases, rising number of ICU beds and high incidence of traumatic injuries provides favorable backgrounds for the market to grow.
However, factors such as expensive diagnostic tests, high ventilator charges, inappropriate reimbursement scenario, risks associated with ventilators are expected to restrict the market growth during the forecast period.
Key players
Some of the key players for the global Ventilator-associated pneumonia market Merck & Co., Inc. (U.S.), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria) and other.
Segmentation
The global Ventilator-associated pneumonia market is segmented on the basis of diagnosis, mode of treatment, and end-user. The Ventilator-associated pneumonia market, by diagnosis categorized into Clinical Examination, Radiological Examination, Microbiological Analysis and others. Microbiological Analysis is further sub-segmented into Blood and pleural fluid cultures, Nonquantitative or semi-quantitative airway sampling and Quantitative cultures of airway specimens. Mode of treatment segment is segmented into Homecare, Hospital care, and others. On the basis of end-user, the market is segmented into Hospitals & Clinics, Research centers, Ambulatory Care Centers and Emergency Medical Services (EMS).      
Regional Market Summary
The Ventilator-associated pneumonia market is dominated by North America owing to the rising geriatric population within the region. The U.S. Census Bureau projected that in 2060, 19.7 million would be of age 85 or older. This influences the growth of this market in this region.
Asia Pacific was projected to be the fastest growing region for the global Ventilator-associated pneumonia market in 2017. The rising geriatric population, increasing healthcare expenditure and growing respiratory disorders in Asia is expected to drive market growth in this region. According to The Asian Development Bank (ADB), the geriatric population in Asia is estimated to reach 923 million by 2050. Thus, this provides favorable backgrounds for the Ventilator-associated pneumonia market to grow.
It is estimated that Europe stood second in the global Ventilator-associated pneumonia market owing to increasing prevalence of lung diseases. According to European respiratory society, more than 50% of deaths are due to lung diseases. Thus, increasing prevalence of lung diseases in this region influences the growth of this market in this region.
The Middle East and Africa holds the least share in the global Ventilator-associated pneumonia market due to the presence of stringent government policies, poor economies, under-developed healthcare infrastructure and low penetration of healthcare services, especially within the African region.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
...TOC Continued
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Monday, 9 December 2019

Cord Blood Banking Services Market 2019 Market Challenge, Driver, Trends & Forecast to 2023

The global cord blood banking services market is expected to exhibit a robust 11.4% CAGR over the forecast period from 2017 to 2023, according to a new report from Market Research Future (MRFR). The global cord blood baking services market is likely to be driven by the growing research into the medical utility of stem cells and cord blood, and the growing establishment of the infrastructure required to create a strong cord blood banking services network.
The umbilical cord blood is a rich source of stem cells and can treat more than 80 genetic diseases. The stem cells also can treat long-lasting diseases such as diabetes, cancer, immune diseases, and blood diseases. Even though a small amount of cord blood can be collected from a single umbilical cord, it comprises a large number of stem cells which can be cultivated and stored for the future use. These cells are collected from hospitals and nursing homes after delivery and stored in cord blood banks (average of 20–25 years) for future use.
Currently, the companies are trying to intensify the awareness about the benefits of cord blood storage. For instance, in 2014, the Institute for Transfusion Medicine and Cord Blood Registry pooled their resources to launch a multi-year initiative for increasing the awareness of cord blood cells.
Factors such as increasing application of cord blood in the treatment of chronic conditions, increasing the focus of federal agencies to set up public banking units, growing awareness regarding this treatment line, and increasing number of facilities across the region are driving the market growth. However, the high cost and probability of non-usage, along with the recommendation driven market by gynecologists are factors hampering the growth of the market.
Key Players
Some of the key players in the global cord blood banking services market are China Cord Blood Corporation (China), Cord Blood America, Inc. (U.S.), CBR Systems, Inc. (U.S.), Cordlife Group Limited (Singapore), Cryo-Cell International, Inc. (U.S.), Cryo-Save AG (Netherland), ViaCord, Inc. (U.S.), Virgin Health Bank (Qatar), California Cryobank Stem Cell Services LLC (U.S.), StemCyte, Inc. (India), Norton Healthcare, Inc. (U.S.), Lifeforce Cryobank Sciences Inc. (U.S.), CordVida (Brazil), CryoHoldco de Latinoamerica, S.A.P.I. De C.V. (Mexico), Vita 34 International (Germany), Maze Cord Blood Laboratories (U.S.), The University of Colorado Cord Blood Bank (U.S.), CorCell (U.S.), Lifebank USA (U.S.), Cryoviva Biotech Pvt. Ltd (India), Genecord (U.S.), AlphaCord (U.S.), FamilyCord (U.S.), Cells4Life (UK), Michigan Blood (U.S.), CariCord (U.S.), LifeCell International Pvt. Ltd (India), Stem Cell Cryobank Inc. (U.S.), Viacord Processing Laboratory (VPL) (U.S.), New Jersey Cord Blood Bank (U.S.), Carter BloodCare (U.S.), Americord Registry (U.S.), and others.
Segmentation
The global cord blood banking services market has been segmented on the basis of storage service, component, application, and end-user.
On the basis of storage service, the global cord blood banking services market can be segmented into public cord blood banks, private cord blood banks, and hybrid cord blood banks.
On the basis of application, the global cord blood banking services market can be segmented into cancers, blood disorders, metabolic disorders, immune disorders, and osteoporosis.
On the basis of component, the global cord blood banking services market can be segmented into cord blood, cord tissue, placenta, and others.
On the basis of end-user, the global cord blood banking services market is segmented into hospitals (medical applications), pharmaceutical research (drug discovery), research institutes (scientific research), and others.
Regional Analysis                     
The global cord blood banking services market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global cord blood banking services market owing to the growing number of service providers, increasing awareness about the long-term benefits of cord blood storage, growing investments in public banking, and reduction in the cost involved in storage. Moreover, the U.S. contributes to a significant market share for the global cord blood banking industry. Factors such growing per capita income, increasing number of storage service providers, and high adoption rate for advanced technologies attributed to the largest market share.
The European cord blood banking services market is the second largest market followed by the Asia Pacific region. The Asia Pacific region is expected to dominate the global cord blood banking services market in terms of growth rate during the forecast period. Though the region presently grasps a minimal share in the global market; it is anticipated to exhibit an enormous growth potential owing to the increasing awareness of stem cell banking and vast improvement in health care reforms in countries such as Malaysia, India, Indonesia, and China. Besides, Asia Pacific is a relatively untapped regional market in comparison with developed regions, which is also a reason why it grants better opportunities for the growth of companies.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cord-blood-banking-services-market-5817
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Research Report and Overview on Chordoma Disease Market, 2019

Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market.
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Regionally, the Americas chordoma disease market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global chordoma disease market owing to the increasing demand for targeted therapies and growing health concerns. As per an estimate by the American Cancer Society, about 3,300 new cases of bone cancer were diagnosed in 2016 with a death toll of about1490. Thus, the high prevalence of chondroid chordomas is the major hurdle in the market growth.
Key Players
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Regional Analysis                    
The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).
The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Epilepsy Diagnosis & Treatment Market Revenue, Opportunity, Forecast and Value Chain Analysis 2019

Increasing prevalence of epilepsy, rising number of traumatic brain injury cases, growing geriatric population, and rising healthcare expenditures are the major drivers for the global epilepsy diagnosis and treatment market. However, high cost of therapeutic surgeries, low per capita healthcare expenditure, and lack of awareness for the disease in emerging economies are estimated to restrain the market growth during the projected period. The global epilepsy diagnosis and treatment market is estimated to grow at an approximate CAGR of 6.3% during the forecast period.
Segmentation
The global epilepsy diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, and end-user. On the basis of type, the market is segmented into idiopathic, cryptogenic, symptomatic, and others. On the basis of diagnosis, the market is segmented into neurological exam, blood test, imaging, and others. The imaging segment is sub-segmented into electroencephalogram, computerized tomography, magnetic resonance imaging, positron emission tomography, and others. On the basis of treatment, the market is segmented into medication, surgery, brain stimulation, and others. The medication segment is sub-segmented into acetazolamide, carbamazepine, clobazam, and others. The surgery segment is sub-segmented into hemispherectomy, corpus callosotomy, resection surgery, and others. The brain stimulation segment is sub-segmented into deep brain stimulation, responsive neurostimulation, and others. On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Regional Analysis
The Americas dominate the global epilepsy diagnosis and treatment market, which can be attributed to the presence of a well-developed healthcare sector and huge patient population within the region. Moreover, increasing number of head trauma cases boosts the American market. Europe holds the second largest market share owing to the availability of funds for research, presence of a well-developed healthcare sector, and government support. Followed by Europe, the Asia Pacific region is projected to be the fastest growing region for the global epilepsy diagnosis and treatment market. Presence of developing healthcare sector, along with emerging economies of the Asia Pacific region boosts the market growth. The Middle East & Africa has the least share in the global epilepsy diagnosis and treatment market, owing to the low per capita healthcare expenditures, lack of awareness for the disease, and stringent government policies, especially in the African region. On the other hand, the Middle East region within the Middle East & Africa is estimated to be fastest growing region due to growing healthcare expenditures and presence of the developed economies, such as Kuwait, Qatar, Dubai, and others.
Key Players
The key players for the global epilepsy diagnosis and treatment market are Pfizer, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), UCB Pharma Ltd. (U.K), Abbott (U.S.), GlaxoSmithKline plc (U.K), Novartis International AG (Switzerland), Sanofi S.A. (France), Shire (Republic of Ireland), Medtronic (U.S.), NeuroWave Systems Inc. (U.S.), Natus Medical Incorporated. (U.S.), Siemens Ltd. (Germany), and others.
Browse Premium Research Report with Tables and Figures @ https://www.marketresearchfuture.com/reports/epilepsy-diagnosis-treatment-market-5647
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)